A Look At InSilico Medicine (SEHK:3696) Valuation After Recent Share Price Pullback

Recent trading moves and company snapshot

InSilico Medicine Cayman TopCo (SEHK:3696) has drawn attention after a recent pullback, with the stock down 1.1% on the day, 23.2% over the past week, and 13.9% over the past month.

Shares last closed at HK$52.35. The company reported annual revenue of $56.239 million and a net loss of $352.316 million. Revenue growth is 37.1%, and net income growth reflects a very large percentage change.

See our latest analysis for InSilico Medicine Cayman TopCo.

That recent pullback follows a wider cool-off, with the 90-day share price return down 31.9%, although the year-to-date share price return of 39.3% still points to earlier strength that now appears to be fading as investors reassess growth potential and risk.

If you are looking beyond a single healthcare AI stock, this is a good moment to scan the wider field and see what stands out in 118 healthcare AI stocks

With revenue rising 37.1% but a net loss of $352.316 million and the stock still up 39.3% year to date, is InSilico Medicine undervalued after this pullback, or is the market already pricing in expectations for future growth?

Price-to-Book of 8.5x: Is it justified?

On a P/B basis, InSilico Medicine Cayman TopCo looks expensive, with the stock trading at 8.5x book value compared with a peer average of about 3x and an Asian Life Sciences industry average of 2.6x.

P/B compares the company’s market value to its net assets. This can be a useful cross check for early stage or loss making healthcare and biotech businesses where earnings are still negative. A higher P/B can reflect investors placing a premium on the asset base, intellectual property, or the potential of the pipeline rather than current profitability.

Here, the P/B of 8.5x suggests the market is pricing in a much richer value for InSilico Medicine’s assets than for many of its regional peers. This is despite the company being currently unprofitable, reporting a net loss of $352.316 million, and carrying a negative return on equity. The gap to both the 3x peer average and the 2.6x wider Asian Life Sciences average is wide. It points to investors assigning a significant premium to the company’s AI driven drug discovery model and growth forecasts.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 8.5x (OVERVALUED)

However, the story can change quickly if clinical results disappoint or if the company continues to report large losses without a clear path to profitability.

Find out about the key risks to this InSilico Medicine Cayman TopCo narrative.

Another view: DCF points the other way

The high P/B ratio paints InSilico Medicine Cayman TopCo as expensive, but our DCF model tells a very different story. With the stock at HK$52.35 and the SWS DCF fair value estimate at HK$145.75, the shares are described as trading at a 64.1% discount. Which signal do you put more weight on?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out InSilico Medicine Cayman TopCo for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 233 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment, do you think the market is getting this story right or missing something important? Take a moment to review the data, weigh the trade off between the company’s risks and potential rewards, and then ground your own view in 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

You have already done the hard work by digging into InSilico Medicine, so do not stop here when other potential opportunities are just a few clicks away.

• Spot potential future leaders early by scanning screener containing 543 high quality undiscovered gems and see which stocks currently sit off most investors’ radar.
• Strengthen your core holdings using the solid balance sheet and fundamentals stocks screener (389 results) to filter for companies with resilient finances and fewer balance sheet surprises.
• Dial down portfolio stress by checking 305 resilient stocks with low risk scores and focus on stocks that score well on risk across several key factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com